Intellia Therapeutics (NTLA) Reports Q4 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results
March 14, 2017 7:15 AM EDTFirst to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levelsFurther established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic developmentExecuted partnering deal with Regeneron Pharmaceuticals, and continued to advance Intellias partnership with Novartis, to support Intellias emerging pipeline with six distinct programs in active research and development, spanning multiple types of genome editingContinued to deploy a diversified approach to maximize CRISPR potential, including pursuing CRISPR... More
